Lung Cancer Research Report Site Specific Group Meeting Tuesday 11th November 2014 Maxine Taylor Senior Research Delivery Manager

Content of report Overview of network changes Overview of research activity New studies for the portfolio Request for research lead

Introduction NIHR Clinical Research Network merged all cancer research networks with all other clinical research networks in England on 1st April 2014 CRN - West of England is one of 15 new networks This new geography does not map exactly to the site specific group geography. It now includes Gloucestershire and Swindon but no longer includes Taunton and Yeovil Taunton and Yeovil are served by the CRN – South West Peninsula I will work closely with my counterpart in South West Peninsula to support this SSG in full

Map showing the 15 Clinical Research Networks in England West of England Population 2.4 million - Budget £13.2 million - 7 Acute Trusts - 2 Mental Health Trusts - CCL Principal Treatment Centre - Full team only since August 1st - Small core support team based at host in Bristol Research will follow patient pathways regardless of network geography

Purpose of the network Translation of national workstreams and objectives (generic and specialty specific) with strategic oversight of research activity within the geography of CRN - West of England in terms of: Portfolio Balance, new studies, feasibility, industry trials Performance Targets, support timely set up, support timely recruitment People Skill mix, workforce flexibility, resources, training

CRN - West of England Management Model Divisions 2 & 6 Divisions 3 & 4 Division 5 Division 1 Maxine Taylor Senior RDM Workforce Development Martine Cross Senior RDM RM&G and Industry Lead Ruth Allen RDM Business Intelligence lead Chantal Sunter PCPIE and Comms Lead Mary Perkins Chief Operating Officer

Network Clinical Divisions Cancer Division 1 Diabetes Renal Stroke Metabolic & endocrine Cardiovascular Division 2 Children Reproductive health & childbirth Genetics Haematology Division 3 Mental Health Dementias & neurodegenerative diseases Neurology Division 4 Primary care Ageing Health services research Oral & dental Dermatology Musculoskeletal Public Health Division 5 ENT Anaesthesia & pain management Surgery Critical care Respiratory Opthalmology Critical care Infectious diseases Hepatology Gastroenterology Division 6

The Clinical Team Dr Steve Falk Clinical Director 6 Divisional Clinical Leads Prof Hugh Barr for Div 1 30 Specialty Leads Sub Specialty Leads Sue Taylor Network Consultant Nurse Clinical Research Teams

Cancer specialty specific objectives NIHR CRN High Level Objectives Set up as fast as you can Recruit as many and as fast as you can All organisations involved Commercial and non commercial portfolio studies Cancer specialty specific objectives Recruitment overall at 20% cancer incidence Recruitment to interventional studies at 7.5% of cancer incidence

How important is cancer on our patch? Cancer incidence 9544 242 recruiting studies £2 million (16%) Funding per incident case approx £220 Funding per recruit £800 Exceeded both recruitment targets for last 2 years Largest non commercial portfolio Benefit from continued good national and international links

West of England specialty portfolio compared to national Total studies 3827 WE total 546 =14%

Recruitment by Trust and study design April – Oct 2014

Recruitment by Trust and study April – Oct 2014

WE Lung portfolio

New studies to discuss: Portfolio search criteria – open to new sites with >12 months to run SPUtNIk - Accuracy and cost-effectiveness of dynamic contrast enhanced computed tomography in the characterisation of solitary pulmonary nodule Closure date – March 2017 CI Dr Steve George, Southampton TAPPS - Evaluating the efficacy of thoracoscopy and talc poudrage versus pleurodesis using talc slurry: a randomised trial to determine the most effective method for the management of malignant pleural effusions in patients with a good performance status Closure date – Jan 2017 CI Dr Nick Maskell, NBT, Bristol MARS2 A study to determine if it is feasible to recruit into a randomised trial comparing (extended) pleurectomy decortication versus no pleurectomy decortication in the multimodality management of patients with malignant pleural mesothelioma IN SET UP. CI – Dr Eric Lim, Royal Brompton, London

New studies continued CEDAR - A Phase II, randomised, open-label study of Gemcitabine/Carboplatin first-line chemotherapy in combination with or without the antisense oligonucleotide Apatorsen (OGX427) in advanced squamous cell lung cancers Closure date – Dec 2016 CI – Prof Peter Schmid, Queen Mary’s, London

Commercial studies NCRN569- LDK378 in ALK+ advanced NSCLC - ASCEND IV - A phase III multicenter, randomized study of oral LDK378 versus standard chemotherapy in previously untreated adult patients with ALK rearranged (ALK-positive), locally advanced or metastatic, non-squamous non-small cell lung cancer NCRN552- ASCEND V - A phase III, multicenter, randomized, open-label study of oral LDK378 versus standard chemotherapy in adult patients with ALK-rearranged (ALK-positive) advanced non-small cell lung cancer who have been treated previously with chemotherapy (platinum doublet) and crizotinib NCRN - 2974 VESTA: Veliparib, carboplatin & paclitaxel in NSCLC - A Randomized, Double-Blind, Multicenter, Phase 3 Study Comparing Veliparib PlusCarboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Previously UntreatedAdvanced or Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC)

Cancer Subspecialty Research Leads Within each network 13 subspecialty research lead roles are identified, mapping onto the national Clinical Studies Groups with the aim of: Providing link between local network and CSGs Promoting the research agenda to clinical colleagues across the network Advising on portfolio planning locally Attendance at annual meeting to discuss portfolio planning and delivery and horizon scan for new studies Supporting the research delivery manager for the cancer specialty Role very similar to SSG Research Lead role

National Clinical Studies Groups PPI Psychosocial & Survivorship Imaging Adv. panel Breast Cancer CSG Brain Tumours CSG Lung Cancer CSG Palliative & Supportive Care Head & Neck CSG Biomarkers Adv. panel Upper GI Cancer CSG Consumer Liaison Group Sarcoma CSG PPI Colorectal Cancer CSG Melanoma CSG Kidney Cancer CSG Primary Care Lymphoma CSG Bladder Cancer CSG Screening, Prevention & Early Diagnosis Haematol. CSG Testis Cancer CSG Prostate Cancer CSG Gynae Cancer CSG Children’s Cancer & Leukaemia Teenage & Young Adult CTRad (Radiotherapy)

LCRN (x15) CRN WE Exec Board COO Clinical Director Partnership Group Clin. Advisory Group Clinical Director COO Division 1 Clinical Lead Division 1 RDM [ +/- other clinical roles] 13 LCRN Subspecialty Leads: Brain cancer H&N cancer Lung cancer Breast cancer Sarcoma Skin Cancer Children/young people Upper GI cancer Colorectal cancer Urological cancer Gynae cancer Haem/lymphoma Pall/Supportive & Psychosocial Research Delivery Teams

Call for Lung sub-specialty lead in CRN - West of England Each SSG already has a research lead We are looking for a research lead in each tumour site to represent the network locally and nationally in terms of developing and supporting the portfolio and providing clinical specialty support to the Research Delivery Manager and Principal Investigators across the network Expenses to attend national meetings will be met by the network Please discuss: Your current research lead continuing and taking on the network representation The nomination of a new research lead who will take on network representation

Contact & reference details Maxine.taylor@nihr.ac.uk Hugh.barr@glos.nhs.uk http://csg.ncri.org.uk/portfolio-maps/ https://www.edge.nhs.uk/Account/Index?ReturnUrl=%2f http://www.crn.nihr.ac.uk/can-help/funders-academics/nihrcrn-portfolio/